Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

NICE guidance on tofacitinib for treating active ulcerative colitis published

Published: 3 December 2018
NICE’s guidance is informed by an evidence review group report prepared by SHTAC

The National Institute for Health and Care Excellence (NICE) has issued guidance to the National Health Service (NHS) on the use of the drug tofacitinib (Xeljanz®) for the treatment of ulcerative colitis, informed by a report produced by SHTAC

NICE’s guidance recommends tofacitinib within its marketing authorisation, as an option for treating moderately to severely active ulcerative colitis in adults when conventional therapy or a biological agent cannot be tolerated or the disease has responded inadequately or lost response to treatment. It is recommended only if the company provides tofacitinib with the discount agreed in a commercial arrangement in which the drug is offered as part of a simple discount patient access scheme.

NICE’s guidance is informed by an evidence review group report prepared by SHTAC, which critically appraised the drug company’s submission to NICE’s Single Technology Appraisal process.

For more information about SHTAC’s research into please visit our Research page.

Privacy Settings